Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J
Published in Neurology
Methodology
Randomized, double-blind, placebo-controlled trial of CoQ10 100 mg three times daily versus placebo for 3 months in adults with migraine.
Key Findings
47.6% of CoQ10 patients had at least a 50% reduction in attack frequency versus 14.4% on placebo; attack frequency and days with nausea fell significantly.
Conclusions
CoQ10 is superior to placebo for migraine prophylaxis and is well tolerated.
Limitations
Small single-centre sample; 3-month duration; predates modern migraine trial standards.
Supplements Studied
47.6% of CoQ10 patients had at least a 50% reduction in attack frequency versus 14.4% on placebo.
Outcomes Measured
CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated.
Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial
47.6% of CoQ10 patients had at least a 50% reduction in attack frequency versus 14.4% on placebo; attack frequency and days with nausea fell significantly.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Swiss Headache Society and university funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.